US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

GSK plc ADRhedged

66.97

-0.0976-0.15%

Post-market: 66.970.00000.00%16:10 EDT

Volume:215

Turnover:14.38K

Market Cap:669.77K

PE:- -

High:66.97

Open:66.84

Low:66.84

Close:67.07

52wk High:85.03

52wk Low:55.75

Shares:10.00K

Float Shares:10.00K

Volume Ratio:1.19

T/O Rate:2.15%

Dividend:2.08

Dividend Rate:3.10%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

GSK Revamps Belantamab Dosing in New Multiple Myeloma Study: What Investors Should Watch

GSK Unit Launches Tender Offer for Nuvalent Acquisition

MT Newswires Live

GSK Discloses Executive Notional ADS Acquisition by U.S. President

GSK launches $124-per-share tender offer to acquire oncology developer Nuvalent

GSK board members boost holdings with coordinated share purchases

GSK's Nuvalent Deal Could Be Rare Case of Profitable Oncology Acquisition -- Market Talk

GSK Expands Treasury Stock Position with June Share Buybacks

GSK Targets Relapsed B-Cell Lymphoma With New Early-Stage Trial

GSK’s ZEAL-1L Lung Cancer Trial Delivers Mixed Readout With Limited Upside for Niraparib

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

MT Newswires Live

GSK, Spero Therapeutics announce FDA approval of Utebzi

GSK wins first US approval for oral carbapenem to treat complicated UTIs

GlaxoSmithKline (GSK) Gets a Sell from Barclays

Sector Update: Healthcare Stocks Advance in Afternoon Trading

MT Newswires Live

GSK Expands Share Buyback, Lifts Treasury Holding to 6.64% of Voting Rights

GSK Opens New Front in Malaria Prevention With First-in-Human Antibody Trial

GSK announces momelotinib granted ODD from U.S. FDA, EMA

GSK's Clonal Myeloid Disorder Treatment Gets Orphan Drug Designation From US, European Regulators

MT Newswires Live

GSK’s momelotinib wins US and EU orphan status for rare VEXAS syndrome

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/GSKH/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":66.9705,"timestamp":1789156800000,"preClose":67.0681,"halted":0,"volume":215,"hourTrading":{"tag":"盘后","latestPrice":66.9705,"preClose":66.9705,"latestTime":"16:10 EDT","volume":6,"amount":401.823,"timestamp":1789157404582,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0014552372886662945,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"Post-Mkt","change":-0.0976,"latestTime":"09-11 18:52:01 EDT","open":66.84,"high":66.9705,"low":66.84,"amount":14383,"amplitude":0.001946,"askPrice":100.44,"askSize":200,"bidPrice":33.48,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":67.0681,"nav":67.507158,"aum":675139.087158,"dividendRate":0.031045,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":66.9705,"preClose":66.9705,"latestTime":"16:10 EDT","volume":6,"amount":401.823,"timestamp":1789157404582,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.194446,"impliedVol":0.3507,"impliedVolPercentile":0.9735},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.194446,"shares":10001,"dividePrice":2.0791,"high":66.9705,"amplitude":0.001946,"preClose":67.0681,"low":66.84,"week52Low":55.7526,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":66.9705,"eps":0,"divideRate":0.031045,"volume":215,"delay":0,"ttmEps":0,"open":66.84,"prevYearClose":68.2031,"prevWeekClose":69.5112,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":70.7456,"twentyDayClose":69.8223,"sixtyDayClose":72.7498},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2646812246","title":"GSK Revamps Belantamab Dosing in New Multiple Myeloma Study: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2646812246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646812246?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:31","pubTimestamp":1782318667,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Tests New Dosing for Key Myeloma Drug in Phase 2 Trial. This new st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-revamps-belantamab-dosing-in-new-multiple-myeloma-study-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-revamps-belantamab-dosing-in-new-multiple-myeloma-study-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4532","BK4007","GSK.UK","BK4585","GSKH","ISBC","GSK","LU1829250122.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646781288","title":"GSK Unit Launches Tender Offer for Nuvalent Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2646781288","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646781288?lang=en_us&edition=fundamental","pubTime":"2026-06-25 00:02","pubTimestamp":1782316952,"startTime":"0","endTime":"0","summary":"GSK  said Wednesday its Harmony Row Acquisition unit commenced a tender offer to purchase all outstanding Class A and Class B shares of Nuvalent  for $124 per share in cash.Following the consummation of the offer, the unit will merge into Nuvalent, which will continue as a direct wholly-owned subsidiary of GlaxoSmithKline LLC.Nuvalent's board of directors recommended that stockholders accept the offer and tender their shares, GSK said.The tender offer and withdrawal rights will expire on July 14, the company added.Price: 51.20, Change: -0.87, Percent Change: -1.67","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4588","GSK","GSKH","BK4139","BK4532","NUVL","BK4007","BK4585","LU1829250122.USD","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645811812","title":"GSK Discloses Executive Notional ADS Acquisition by U.S. President","url":"https://stock-news.laohu8.com/highlight/detail?id=2645811812","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645811812?lang=en_us&edition=fundamental","pubTime":"2026-06-24 22:32","pubTimestamp":1782311549,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has disclosed a transaction involving Maya Martinez-Davis, President of its U.S. business, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-discloses-executive-notional-ads-acquisition-by-u-s-president?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-discloses-executive-notional-ads-acquisition-by-u-s-president?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","BK4532","BK4007","BK4585","GSKH","GSK","LU1829250122.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645781620","title":"GSK launches $124-per-share tender offer to acquire oncology developer Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2645781620","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645781620?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:58","pubTimestamp":1782309489,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has launched a cash tender offer, through its subsidiary Harmony Row Acquisition Co., to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-launches-124-per-share-tender-offer-to-acquire-oncology-developer-nuvalent?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-launches-124-per-share-tender-offer-to-acquire-oncology-developer-nuvalent?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LU1829250122.USD","NUVL","BK4532","BK4139","BK4007","GSK","GSK.UK","GSKH","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645837762","title":"GSK board members boost holdings with coordinated share purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2645837762","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645837762?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:07","pubTimestamp":1782227251,"startTime":"0","endTime":"0","summary":"An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has disclosed a series of share purchases by its senior board members, including...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-board-members-boost-holdings-with-coordinated-share-purchases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-board-members-boost-holdings-with-coordinated-share-purchases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","BK4588","GSK","GSKH","LU1829250122.USD","BK4532","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645888836","title":"GSK's Nuvalent Deal Could Be Rare Case of Profitable Oncology Acquisition -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2645888836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645888836?lang=en_us&edition=fundamental","pubTime":"2026-06-23 13:58","pubTimestamp":1782194280,"startTime":"0","endTime":"0","summary":"0557 GMT - GSK's proposed acquisition of Nuvalent could be a rare case of an oncology deal by a big pharmaceutical company at an excellent price that turns out to be profitable, Bernstein analysts say in a research note. Nuvalent's most advanced products--lung-cancer drugs candidates neladalkib and zidesamtinib--could generate total peak revenue of $9.8 billion, according to Bernstein. This is 56% higher than the current consensus forecast, the analysts say. The incremental sales should be very profitable for GSK, which leads Bernstein to estimate Nuvalent could lift GSK's 2036 adjusted EPS by 18%. \"We thus see this [acquisition] as another crucial piece in the jigsaw which restores GSK to sustainable growth and transforms investors' perceptions,\" the analysts say. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","GSKH","BK4532","BK4007","GSK.UK","BK4585","NUVL","BK4539","BK4588","LU1829250122.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645731440","title":"GSK Expands Treasury Stock Position with June Share Buybacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2645731440","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645731440?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:24","pubTimestamp":1782138247,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK has continued its ongoing share buyback programme, repurchasing more than one mill...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-expands-treasury-stock-position-with-june-share-buybacks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-expands-treasury-stock-position-with-june-share-buybacks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK.UK","GSK","BK4585","LU1829250122.USD","BK4532","BK4007","BK4588","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644080970","title":"GSK Targets Relapsed B-Cell Lymphoma With New Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644080970","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644080970?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:36","pubTimestamp":1781800606,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The study titled “A Phase 1/2 Open-label, Multi-center Study to Evaluat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-targets-relapsed-b-cell-lymphoma-with-new-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-targets-relapsed-b-cell-lymphoma-with-new-early-stage-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1829250122.USD","GSK","BK4007","BK4585","BK4588","GSK.UK","GSKH","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644208015","title":"GSK’s ZEAL-1L Lung Cancer Trial Delivers Mixed Readout With Limited Upside for Niraparib","url":"https://stock-news.laohu8.com/highlight/detail?id=2644208015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644208015?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:30","pubTimestamp":1781800252,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has reported results for ZEAL-1L, a Phase 3 trial officially titled...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-zeal-1l-lung-cancer-trial-delivers-mixed-readout-with-limited-upside-for-niraparib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-zeal-1l-lung-cancer-trial-delivers-mixed-readout-with-limited-upside-for-niraparib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZEAL","BK4532","GSK.UK","LU1829250122.USD","BK4585","BK4139","GSKH","GSK","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644723527","title":"Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644723527","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644723527?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:36","pubTimestamp":1781714160,"startTime":"0","endTime":"0","summary":"First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are trea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313706/0/en/Utebzi-tebipenem-pivoxil-approved-in-the-US-for-adults-with-complicated-urinary-tract-infections-cUTIs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","LU1829250122.USD","BK4007","GSKH","BK4006","BK4532","BK4588","GSK","AP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644740373","title":"GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2644740373","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644740373?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:00","pubTimestamp":1781712056,"startTime":"0","endTime":"0","summary":"GSK  and Spero Therapeutics  said Wednesday that the US Food and Drug Administration has approved Utebzi as treatment for complicated urinary tract infections, including pyelonephritis, in adults.Utebzi, or tebipenem pivoxil, is the first and only oral carbapenem antibiotic approved in the US and is expected to become available by the end of 2026, the companies said.The approval was based on phase 3 trial data showing Utebzi's non-inferiority to intravenous imipenem-cilastatin, with tebipenem pivoxil achieving an overall success rate of 58.5% against 60.2% for imipenem-cilastatin, according to a statement. Tebipenem pivoxil's safety profile is also \"generally similar\" to that of imipenem-cilastatin, the companies said.GSK shares were up about 1%, while Spero stock was down more than 14% in Wednesday trading.Price: 52.72, Change: +0.50, Percent Change: +0.96","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4585","BK4007","BK4532","LABU","GSK","GSKH","SPRO","BK4139","BK4588","LU1829250122.USD","GSK.UK","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644674796","title":"GSK, Spero Therapeutics announce FDA approval of Utebzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2644674796","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644674796?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:17","pubTimestamp":1781709438,"startTime":"0","endTime":"0","summary":"GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatme...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-spero-therapeutics-announce-fda-approval-of-utebzi-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-spero-therapeutics-announce-fda-approval-of-utebzi-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4539","SPRO","LABU","BK4139","GSKH","BK4585","GSK","LENZ","BK4588","LU1829250122.USD","BK4007","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644774799","title":"GSK wins first US approval for oral carbapenem to treat complicated UTIs","url":"https://stock-news.laohu8.com/highlight/detail?id=2644774799","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644774799?lang=en_us&edition=fundamental","pubTime":"2026-06-17 23:12","pubTimestamp":1781709144,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK and Spero Therapeutics have secured US FDA approval for Utebzi (tebipenem pivoxil)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-wins-first-us-approval-for-oral-carbapenem-to-treat-complicated-utis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-wins-first-us-approval-for-oral-carbapenem-to-treat-complicated-utis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4585","GSK","BK4532","BK4588","GSKH","BK4007","GSK.UK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644060710","title":"GlaxoSmithKline (GSK) Gets a Sell from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2644060710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644060710?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:36","pubTimestamp":1781692578,"startTime":"0","endTime":"0","summary":"Barclays analyst James Gordon CFA maintained a Sell rating on GlaxoSmithKline today and set a price target of £18.00. Gordon CFA covers the Healthc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-sell-from-barclays-blurbs-news-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/glaxosmithkline-gsk-gets-a-sell-from-barclays-blurbs-news-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CFA","BK4532","GSKH","BK4585","GSK","LU1829250122.USD","BK4588","BK4007","GSK.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644761439","title":"Sector Update: Healthcare Stocks Advance in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2644761439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644761439?lang=en_us&edition=fundamental","pubTime":"2026-06-17 01:29","pubTimestamp":1781630950,"startTime":"0","endTime":"0","summary":"Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF  each adding 0.2%.The iShares Biotechnology ETF  was down 0.2%.In corporate news, GSK  said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk  plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly  submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech  shares jumped past 10% after it said Tuesday it has received a US pate","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0708995401.HKD","LLII","LU2112291526.USD","LU1093756168.USD","LU0109391861.USD","LU0256863902.USD","LU1057294990.SGD","ONCY","LU0786609619.USD","SG9999001176.SGD","LU1804176565.USD","LU2023250504.SGD","LU2361044865.SGD","LU2089283258.USD","LU1868836757.USD","LU1989771016.USD","LU2168564495.EUR","LU0385154629.USD","LU2237443465.HKD","LU2089284900.SGD","IE00BJJMRX11.SGD","LU2552382058.USD","LU0823416689.USD","LU0225283273.USD","SG9999015986.USD","LU0323591593.USD","LU0320765992.SGD","ELIS","LU0061475181.USD","GB00BDT5M118.USD","LU0417517546.SGD","IE00BJLML261.HKD","IE00BN29S564.USD","BK4581","LU2471134523.USD","IE00BKPKM429.USD","LU2357305700.SGD","LU0471298777.SGD","SG9999001176.USD","LU2168564222.USD","SG9999018865.SGD","LU1232071149.USD","IE0005OL40V9.USD","LU0133085943.USD","LU1974910355.USD","LU2491049909.HKD","LU0471298694.HKD","LU2237443978.SGD","IE00BJJMRY28.SGD","IE00BK4W5L77.USD","LU2461242641.AUD","LU0154236417.USD","LU2491050154.USD","IE00BJT1NW94.SGD","IE00BKVL7J92.USD","BK4007","LU0456855351.SGD","LU1145028129.USD","LU0823434740.USD","LU1623119135.USD","LU2023250330.USD","IE00BFSS8Q28.SGD","SG9999015945.SGD","GSKH","LU2168563687.JPY","SG9999015952.SGD","LU0158827948.USD","LU0820561909.HKD","LU2756315664.SGD","LU2237443895.HKD","IE0009355771.USD","LU2237443382.USD","LU2417539215.USD","SG9999017495.SGD","LU0787776722.HKD","LU1064131342.USD","LU2491050071.SGD","LU2063271972.USD","LU1814569148.SGD","LU0114720955.EUR","LU1868837300.USD","LU2756315318.SGD","LU1093756325.SGD","LU2552382215.SGD","NVOX","LU2552382132.HKD","LU1366192091.USD","LU0672654240.SGD","LU1629891620.HKD","LU0882574139.USD","BK4139","LU1069344957.HKD","LU0203201768.USD","LU1548497426.USD","LU0964807845.USD","LU0640476718.USD","GSK.UK","LU0238689110.USD","LU0353189763.USD","LU0820561818.USD","LU2750360641.GBP","LU1868837136.USD","SGXZ31699556.SGD","BK4532","LU2471134952.CNY","LU1868836914.USD","LU0882574055.USD","LU2023251221.USD","IE00BKDWB100.SGD","LU1720051017.SGD","IE00BFSS7M15.SGD","LU0058720904.USD","SG9999018857.SGD","IE00B1XK9C88.USD","LU0823434583.USD","LU0094547139.USD","IE00B4JS1V06.HKD","LU0354030511.USD","LU1323610961.USD","LU0158827781.USD","LU0683600562.USD","LU2236285917.USD","LU2468319806.SGD","LU0256863811.USD","LU1829250122.USD","BK4588","LU0289739699.SGD","IE0004445015.USD","SG9999013999.USD","SGXZ81514606.USD","LU1061106388.HKD","LU2746668461.USD","LU0106261372.USD","LU1551013342.USD","LU1291159041.SGD","LU0353189680.USD","IE00BFTCPJ56.SGD","LU0820562030.AUD","IE00B4R5TH58.HKD","LU1127390331.HKD","LU1267930730.SGD","IE00BJJMRZ35.SGD","LU2264538146.SGD","LU2471134879.HKD","LU1035775433.USD","BK4533","LU0689472784.USD","LU1917777945.USD","LU2213496289.HKD","SGXZ57979304.SGD","LU2271345857.HKD","LU2896262040.SGD","NVOH","LLYX","LU0109394709.USD","LU0354030438.USD","LU1023059063.AUD","LU0466842654.USD","SG9999014880.SGD","LU0097036916.USD","LU0006306889.USD","IE0004445239.USD","LU2106854487.HKD","SG9999014898.SGD","NVO","IE00B2B36J28.USD","LU2111349929.HKD","IE00BK4W5M84.HKD","LU0079474960.USD","LU0096364046.USD","LU2361045086.USD","LLY","LU2168564065.EUR","IE00B1BXHZ80.USD","LU2089984988.USD","LU0432979614.USD","GSK","LU0943347566.SGD","LU1551013425.SGD","LU2211815571.USD","LU2602419157.SGD","LU2456880835.USD","LU0316494557.USD","LU2361044949.HKD","LU2237443622.USD","LU0198837287.USD","IE0002141913.USD","SGXZ51526630.SGD","LU0266013472.USD","SG9999015978.USD","LLYZ","LU2746668974.SGD","IE00BZ1G4Q59.USD","LU0122379950.USD","LU0210536198.USD","BK4599","LU2471134796.USD","IE0001KFT4U8.USD","LU1712237335.SGD","LU1720051108.HKD","LU2750360997.AUD","LU0889565916.HKD","LU2028103732.USD","LU2237443549.SGD","IE00BWXC8680.SGD","LU2265009873.SGD","LU2462157665.USD","SGXZ99366536.SGD","LU1868836591.USD","IE00B7KXQ091.USD","LU1983299246.USD","BK4585","LU1988902786.USD","IE00B775H168.HKD","BK4516","LU2237438978.USD","LU2360106947.USD","SG9999014906.USD","LU2108987350.USD","LU0203202063.USD","SG9999014914.USD","LU2087625088.SGD","LU2324357040.USD","LU2168564149.EUR","ELIL","LU0320765059.SGD","LU1280957306.USD","LU0234572021.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643201675","title":"GSK Expands Share Buyback, Lifts Treasury Holding to 6.64% of Voting Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2643201675","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643201675?lang=en_us&edition=fundamental","pubTime":"2026-06-15 22:01","pubTimestamp":1781532116,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has continued to execute its existing share buyback programme, repurchasing more than 1.1 m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-expands-share-buyback-lifts-treasury-holding-to-6-64-of-voting-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-expands-share-buyback-lifts-treasury-holding-to-6-64-of-voting-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","GSK","BK4585","BK4588","GSK.UK","GSKH","LU1829250122.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643944592","title":"GSK Opens New Front in Malaria Prevention With First-in-Human Antibody Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643944592","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643944592?lang=en_us&edition=fundamental","pubTime":"2026-06-13 00:31","pubTimestamp":1781281877,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK has launched a first-in-human trial of its new antibody GSK4425689A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsk-opens-new-front-in-malaria-prevention-with-first-in-human-antibody-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsk-opens-new-front-in-malaria-prevention-with-first-in-human-antibody-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSK","GSKH","BK4532","BK4007","GSK.UK","BK4585","BK4588","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267278","title":"GSK announces momelotinib granted ODD from U.S. FDA, EMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267278","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267278?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:07","pubTimestamp":1781262453,"startTime":"0","endTime":"0","summary":"GSK (GSK) announced that momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation, ODD, from th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gsk-announces-momelotinib-granted-odd-from-u-s-fda-ema-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4081","BK4532","BK4183","BK4585","BK4007","GSK.UK","GSK","GSKH","ODD","LU1829250122.USD","BK4588","EMA","LABU","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642269788","title":"GSK's Clonal Myeloid Disorder Treatment Gets Orphan Drug Designation From US, European Regulators","url":"https://stock-news.laohu8.com/highlight/detail?id=2642269788","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642269788?lang=en_us&edition=fundamental","pubTime":"2026-06-12 17:31","pubTimestamp":1781256686,"startTime":"0","endTime":"0","summary":"GSK's  momelotinib has received orphan drug designation from the US Food and Drug Administration and the European Medicines Agency for the treatment of the VEXAS syndrome, the company said on Friday.VEXAS syndrome is a severe, progressive condition with no approved treatments and a 30% to 40% five-year mortality rate, it added.The British pharmaceutical giant has planned a phase II/III trial to evaluate the efficacy and safety of momelotinib in VEXAS syndrome that will support upcoming global regulatory submissions.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1829250122.USD","BK4588","EPV","BK4532","GSKH","GSK","GSK.UK","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642524242","title":"GSK’s momelotinib wins US and EU orphan status for rare VEXAS syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2642524242","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642524242?lang=en_us&edition=fundamental","pubTime":"2026-06-12 14:08","pubTimestamp":1781244512,"startTime":"0","endTime":"0","summary":"An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has secured Orphan Drug Designation from both the U.S. and European regula...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-momelotinib-wins-us-and-eu-orphan-status-for-rare-vexas-syndrome?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-momelotinib-wins-us-and-eu-orphan-status-for-rare-vexas-syndrome?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","BK4588","GSK","EPV","GSKH","LU1829250122.USD","BK4532","GSK.UK","BK4156"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}